Second-Generation Tyrosine Kinase Inhibitors Combined With Stem Cell Transplantation in Patients With Imatinib-Refractory Chronic Myeloid Leukemia

Allo-SCT has a satisfactory outcome when combined with 2nd-generation TKI, which could provide a good quality of remission before transplantation and prevent relapse after transplantation.